Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches

• Published in: Journal of clinical pharmacology 2021-07, Vol.61 (7), p.857-870
• Main Authors: McPhail, Brooks T., Emoto, Chie, Butler, Dawn, Fukuda, Tsuyoshi, Akinbi, Henry, Vinks, Alexander A.
• Format: Article
• Language: English
• Subjects: Buprenorphine; Buprenorphine - pharmacokinetics; Buprenorphine - therapeutic use; Cytochrome P-450 CYP3A - metabolism; Dosage; Dose-Response Relationship, Drug; Drug therapy; Drug withdrawal; Humans; Infant, Newborn; Infants; Intrauterine exposure; Methadone; Methadone - pharmacokinetics; Methadone - therapeutic use; Models, Biological; Morphine; Morphine - pharmacokinetics; Morphine - therapeutic use; Narcotics; Narcotics - administration & dosage; Narcotics - pharmacokinetics; Narcotics - pharmacology; Narcotics - therapeutic use; Neonatal abstinence syndrome; Neonatal Abstinence Syndrome - drug therapy; neonatal opioid withdrawal syndrome (NOWS); Neonates; Newborn babies; Opiate Substitution Treatment - methods; Opioid-Related Disorders - drug therapy; Opioids; Pharmacodynamics; Pharmacokinetics; Psychotropic drugs; Withdrawal
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/jcph.1811

Chronic intrauterine exposure to psychoactive drugs often results in neonatal opioid withdrawal syndrome (NOWS). When nonpharmacologic measures are insufficient in controlling NOWS, morphine, methadone, and buprenorphine are first‐line medications commonly used to treat infants with NOWS because of in utero exposure to opioids. Research suggests that buprenorphine may be the leading drug therapy used to treat NOWS when compared with morphine and methadone. Currently, there are no consensus or standardized treatment guidelines for medications prescribed for NOWS. Opioids used to treat NOWS exhibit large interpatient variability in pharmacokinetics (PK) and pharmacodynamic (PD) response in neonates. Organ systems undergo rapid maturation after birth that may alter drug disposition and exposure for any given dose during development. Data regarding the PK and PD of opioids in neonates are sparse. Pharmacometric methods such as physiologically based pharmacokinetic and population pharmacokinetic modeling can be used to explore factors predictive of some of the variability associated with the PK/PD of opioids in newborns. This review discusses the utility of pharmacometric techniques for enhancing precision dosing in infants requiring opioid treatment for NOWS. Applying these approaches may contribute to optimizing the outcome by reducing cumulative drug exposure, mitigating adverse drug effects, and reducing the burden of NOWS in neonates.